Moderna is also studying booster doses of the COVID-19 vaccine for all pediatric cohorts.
Formulary Watch
Latest News
All News
Advertisement
Javier Gonzalez, Pharm.D., Abarca’s chief growth and commercial officer, talks about Assura, the PBM’s net cost pricing solution, which provides more predictability to drug costs and guarantees an annual fixed cost.
Now called Camzyos, the therapy is first-in-class and treats the underlying cause of the disease. It is expected to be available next week.
Vivjoa is an oral therapy and the first for chronic yeast infections. It is expected to be available in the second quarter of 2022.
Ultomiris is the first approval for a long-acting C5 complement inhibitor for the treatment of generalized myasthenia gravis, a rare, chronic, autoimmune neuromuscular disease.
Pramod John, CEO, and Bhargav Raman, M.D., director, clinical product, at Vivio Health, discuss how their system can match patients to therapies based on data.
Veklury gets full approval for use in children and the Biden Administration commits to expanding the Test-to Treat initiative and getting COVID-19 anti-virals to those who need them.
The FDA has set a Prescription Drug User Fee Act date for tremelimumab during the fourth quarter of 2022.
Higher than normal levels of nitrosamine have been detected. Long-term exposure to high amounts of nitrosamine can lead to cancer.
The FDA is seeking input from committee members about the phosphate lowering effect seen in trials for tenapanor, which now has the brand name of Xphozah.
Advertisement
The FDA is expected to make decisions on several products later this week, including mavacamten, Qelbree, meloxicam-rizatriptan, surufatinib and toripalimab.
Phase 3 trials show CSF-1, a low-dose pilocarpine, met clinical endpoints for improving presbyopia, or age-related blurry vision.
The World Health Organization now recommends Paxlovid and Veklury for non-severe COVID-19 at high risk of hospitalization but still advises against use in mild disease with low risk of hospitalization.
The EMA’s Committee for Medicinal Products for Human Use indicated that the data provided is not sufficient for marketing authorization.
The new PDUFA date for is Sept. 8, 2022, for daxibotulinumtoxinA, Revance’s therapy to treat frown lines.
The FDA has approved miglustat for Gaucher disease. Breckenridge launches pencillamine for Wilson’s disease and lacosamide for seizure disorder.
An estimated additional 81 million prescriptions were abandoned at the pharmacy because of high out-of-pocket costs for patients.
Carole Florman, policy fellow at CancerCare, talks about how utilization management can have unintended consequences for patients.
Teva Pharmaceutical and MedinCell, the drug’s developers, didn’t provide a reason for the complete response letter.
The FDA has granted orphan drug designation to a potential first-in-class therapy for scleroderma and a PD-1 inhibitor for small cell lung cancer.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 1, 2023, for daprodustat.
The PDUFA date for Enhertu in the lung cancer indication is in the third quarter of 2022.
Dr. Caroline Carney of Magellan Healthcare discusses the psychedelics in the pipeline for treating mental health conditions.
A Parkinson’s therapy, a treatment for seizures, a drug used in the treatment of heart failure, and a therapy for a rare disease have been removed from Prime’s Medicare formularies.
Zosyn’s label was updated to warn about the risk of a severe immune response called hemophagocytic lymphohistiocytosis.
Generic launches include equivalents of Combigan, Abraxane, Cytotec, Solu-Medrol, and Tobradex.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Ashley Holzworth-Nash, Pharm.D., Evernorth
2
Arpit Patel. Pharm.D., MedImpact
3
CMS sets the 2027 Part D bid amount at $296.05, will end premium subsidy program
4
Investigational non-opioid LTG-001 reduced acute pain in phase 2b trial
5